Keymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., . . . Pipeleers, D. (2010). Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
Chicago-čujuhus (17. p.)Keymeulen, B., et al. Four-year Metabolic Outcome of a Randomised Controlled CD3-antibody Trial in Recent-onset Type 1 Diabetic Patients Depends on Their Age and Baseline Residual Beta Cell Mass. 2010.
MLA-čujuhus (9. p.)Keymeulen, B., et al. Four-year Metabolic Outcome of a Randomised Controlled CD3-antibody Trial in Recent-onset Type 1 Diabetic Patients Depends on Their Age and Baseline Residual Beta Cell Mass. 2010.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.